[Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy-- AKT/m-TOR Pathway and Resistance to Cancer Therapy].
Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.
['Spirina|Liudmila V|LV|', 'Kondakova|Irina V|IV|', 'Tarasenko|Natalia V|NV|', 'Slonimskaya|Elena M|EM|', 'Usynin|Evgeny A|EA|', 'Gorbunov|Alexey K|AK|', 'Yurmazov|Zahar A|ZA|', 'Chigevskaya|Svetlana Yu|SY|']
D000818:Animals D014408:Biomarkers, Tumor D019008:Drug Resistance, Neoplasm D006801:Humans D058990:Molecular Targeted Therapy D009369:Neoplasms D051057:Proto-Oncogene Proteins c-akt D015398:Signal Transduction D058570:TOR Serine-Threonine Kinases
Resistance to cancer therapy Molecular markers AKT/m-TOR signaling pathway